Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

TG Therapeutics (TGTX) stock spikes as Roche (RHHBY) fails in a Phase 3 trial for a high dose version of its multiple ...

Despite the trial not meeting its primary endpoint, the high dose was well tolerated, with a safety profile comparable to the approved 600 mg dose and no new safety signals observed. These findings ...

Commvault (CVLT) announced the appointment of Bill O’Connell as its Chief Security Officer. O’Connell joins Commvault with nearly 20 years of ...

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI ...

(Lenin Nolly/Zuma Press) Commerce Secretary Howard Lutnick used a TV appearance to recommend the public buy shares in Elon Musk's car company, saying: "It's unbelievable that this guy's stock is ...

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Shares of RHHBY stock opened at $43.36 on Thursday. Roche Holding AG has a 52-week low of $29.20 and a 52-week high of $44.31. The company has a debt-to-equity ratio of 0.86, a current ratio of 1. ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.